Against this backdrop, Sun Pharma is strengthening its presence in complex biologics and specialty therapies as part of its long-term growth strategy.

A major focus of the presentation is the proposed combination with Organon, which is expected to create a $12.4 billion revenue platform with a more diversified global business mix.

The combined entity will derive around 27 percent of its revenue from innovative medicines, 51 percent from established brands and branded generics, 11 percent from biosimilars, and the remainder from generics and API-related businesses.

The presentation outlines that the transaction marks a structural shift for Sun Pharma, moving it further away from a predominantly generics-led model toward a balanced portfolio with greater exposure to innovation-driven therapies. Organon’s strong position in women’s health, contraception and fertility is expected to significantly enhance Sun’s presence in this high-growth therapeutic area, which will now form a key pillar of its innovative medicines portfolio.

In established brands, Sun Pharma’s existing portfolio of over 100 branded generics products is expected to be complemented by Organon’s 50-plus established brands. The investor presentation highlights opportunities for cross-market expansion, lifecycle management and in-licensing, supported by Sun’s proven branded generics execution model.

On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms, alongside Organon’s commercial strength in developed markets. This is expected to unlock new growth channels, particularly in Europe and other advanced markets where Organon has a strong retail and hospital presence.

The combined entity will have a footprint across more than 150 markets, supported by a global commercial organisation of over 24,000 employees. The investor presentation also highlights that 18 markets will each contribute more than $100 million in revenue, underlining the scale of the integrated platform.

China is identified as a key strategic growth market, with a healthcare opportunity exceeding $150 billion and a rapidly expanding innovation pipeline of more than 2,000 molecules in development. Organon’s established presence in the country is expected to accelerate Sun Pharma’s expansion across both established and innovative medicines.